301080 百普赛斯
已收盘 07-19 15:00:00
资讯
新帖
简况
百普赛斯(301080)7月12日主力资金净卖出94.77万元
证券之星 · 07-15
百普赛斯(301080)7月12日主力资金净卖出94.77万元
百普赛斯新提交3件商标注册申请
证券之星 · 06-29
百普赛斯新提交3件商标注册申请
百普赛斯(301080.SZ)拟10股派9元 于7月5日除权除息
智通财经 · 06-28
百普赛斯(301080.SZ)拟10股派9元 于7月5日除权除息
百普赛斯:2023年度,扣除特定急性呼吸道传染病相关产品后,公司美洲区收入2.29亿元,占比46%
证券之星 · 06-27
百普赛斯:2023年度,扣除特定急性呼吸道传染病相关产品后,公司美洲区收入2.29亿元,占比46%
百普赛斯涨5.29%,开源证券二个月前给出“买入”评级
证券之星 · 06-26
百普赛斯涨5.29%,开源证券二个月前给出“买入”评级
百普赛斯(301080)6月24日主力资金净卖出322.41万元
证券之星 · 06-25
百普赛斯(301080)6月24日主力资金净卖出322.41万元
百普赛斯新提交6件商标注册申请
证券之星 · 06-24
百普赛斯新提交6件商标注册申请
百普赛斯(301080)6月21日主力资金净买入416.08万元
证券之星 · 06-24
百普赛斯(301080)6月21日主力资金净买入416.08万元
百普赛斯(301080)6月11日主力资金净卖出324.51万元
证券之星 · 06-12
百普赛斯(301080)6月11日主力资金净卖出324.51万元
百普赛斯:陈劲秋女士因个人原因申请辞去公司副总经理职务,她的离职不会影响公司相关工作的正常进行
证券之星 · 05-24
百普赛斯:陈劲秋女士因个人原因申请辞去公司副总经理职务,她的离职不会影响公司相关工作的正常进行
百普赛斯(301080)5月15日主力资金净卖出1370.52万元
证券之星 · 05-16
百普赛斯(301080)5月15日主力资金净卖出1370.52万元
百普赛斯:公司将按照相关法律法规在定期报告中及时披露相应时点的股东持股情况
证券之星 · 05-13
百普赛斯:公司将按照相关法律法规在定期报告中及时披露相应时点的股东持股情况
天风证券:给予百普赛斯买入评级
证券之星 · 05-08
天风证券:给予百普赛斯买入评级
5月8日百普赛斯涨6.75%,圆信永丰兴源灵活配置混合A基金重仓该股
证券之星 · 05-08
5月8日百普赛斯涨6.75%,圆信永丰兴源灵活配置混合A基金重仓该股
百普赛斯(301080)5月7日主力资金净买入3028.59万元
证券之星 · 05-08
百普赛斯(301080)5月7日主力资金净买入3028.59万元
百普赛斯涨10.67%,开源证券一周前给出“买入”评级
证券之星 · 05-06
百普赛斯涨10.67%,开源证券一周前给出“买入”评级
开源证券:给予百普赛斯买入评级
证券之星 · 04-26
开源证券:给予百普赛斯买入评级
东吴证券:给予百普赛斯买入评级
证券之星 · 04-25
东吴证券:给予百普赛斯买入评级
百普赛斯(301080)2024年一季报简析:增收不增利
证券之星 · 04-25
百普赛斯(301080)2024年一季报简析:增收不增利
百普赛斯(301080)3月31日股东户数1.43万户,较上期增加9.16%
证券之星 · 04-24
百普赛斯(301080)3月31日股东户数1.43万户,较上期增加9.16%
公司概况
公司名称:
北京百普赛斯生物科技股份有限公司
所属行业:
研究和试验发展
上市日期:
2021-10-18
主营业务:
北京百普赛斯生物科技股份有限公司是一家专业提供重组蛋白等关键生物试剂产品及技术服务的高新技术企业。公司主要产品为重组蛋白、试剂盒、抗体、生物分析检测服务。2019年5月获得“中国外贸出口先导指数样本企业”荣誉称号、2020年3月入围科技部疫情防控先进技术成果和创新产品。公司于2020年10月获得亦庄高科技高成长20强;于2020年7月获得2020年北京市“专精特新”中小企业的荣誉称号。
发行价格:
112.50
{"stockData":{"symbol":"301080","market":"SZ","secType":"STK","nameCN":"百普赛斯","latestPrice":35.56,"timestamp":1721372586000,"preClose":35.45,"halted":0,"volume":1158850,"delay":0,"floatShares":67028900,"shares":120000000,"eps":1.1602,"marketStatus":"已收盘","marketStatusCode":5,"change":0.11,"latestTime":"07-19 15:00:00","open":35.37,"high":36.13,"low":34.88,"amount":41129500,"amplitude":0.0353,"askPrice":35.65,"askSize":10,"bidPrice":35.56,"bidSize":229,"shortable":0,"etf":0,"ttmEps":1.1602,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721611800000},"adr":0,"adjPreClose":35.45,"symbolType":"stock","openAndCloseTimeList":[[1721352600000,1721359800000],[1721365200000,1721372400000]],"highLimit":39,"lowLimit":31.91,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":120000000,"pbRate":1.62,"roa":"--","roe":"1.18%","epsLYR":1.2801,"committee":0.870183,"marketValue":4267000000,"floatMarketCap":2384000000,"peRate":30.649888,"changeRate":0.0031,"turnoverRate":0.0173,"status":0},"requestUrl":"/m/hq/s/301080/wiki","defaultTab":"wiki","newsList":[{"id":"2451652945","title":"百普赛斯(301080)7月12日主力资金净卖出94.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451652945","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451652945?lang=zh_cn&edition=full","pubTime":"2024-07-15 09:15","pubTimestamp":1721006116,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月12日收盘,百普赛斯报收于35.8元,上涨2.43%,换手率2.93%,成交量1.96万手,成交额7061.99万元。7月12日的资金流向数据方面,主力资金净流出94.77万元,占总成交额1.34%,游资资金净流出267.32万元,占总成交额3.79%,散户资金净流入362.09万元,占总成交额5.13%。百普赛斯主营业务:提供重组蛋白等关键生物试剂产品及技术服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500002436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2447661781","title":"百普赛斯新提交3件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2447661781","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447661781?lang=zh_cn&edition=full","pubTime":"2024-06-29 12:31","pubTimestamp":1719635497,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日北京百普赛斯生物科技股份有限公司新提交3件商标注册申请。商标申请详情如下:今年以来北京百普赛斯生物科技股份有限公司新申请注册商标38件,截止目前公司共持有注册商标222件,另有68件商标尚在注册申请中。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062900013643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2446505610","title":"百普赛斯(301080.SZ)拟10股派9元 于7月5日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2446505610","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446505610?lang=zh_cn&edition=full","pubTime":"2024-06-28 19:34","pubTimestamp":1719574492,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百普赛斯(301080.SZ)公告,公司2023年年度权益分派拟:向全体股东每10股派发现金股利9元(含税)。除权除息日为:2024年7月5日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301080","BK0216"],"gpt_icon":0},{"id":"2446053861","title":"百普赛斯:2023年度,扣除特定急性呼吸道传染病相关产品后,公司美洲区收入2.29亿元,占比46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446053861","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446053861?lang=zh_cn&edition=full","pubTime":"2024-06-27 19:01","pubTimestamp":1719486089,"startTime":"0","endTime":"0","summary":"证券之星消息,百普赛斯06月27日在投资者关系平台上答复投资者关心的问题。2023年度,扣除特定急性呼吸道传染病相关产品后,公司美洲区收入2.29亿元,占比46%。公司将持续保持对海外政策和市场动态的关注,及时有效采取措施应对风险,稳妥有效的实现公司海外战略。为吸引和留住优秀人才,充分调动公司员工的积极性,自上市后公司已推出两期激励计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700034986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2446435982","title":"百普赛斯涨5.29%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2446435982","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446435982?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:30","pubTimestamp":1719390619,"startTime":"0","endTime":"0","summary":"今日百普赛斯涨5.29%,收盘报36.8元。2024年4月26日,开源证券研究员余汝意,汪晋发布了对百普赛斯的研报《公司信息更新报告:常规业务持续高增长,高费用影响短期利润》,该研报对百普赛斯给出“买入”评级。此外,东吴证券研究员朱国广,张坤,国元证券研究员马云涛,朱仕平近期也对该股发布了研报,同样给出“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为西南证券的杜向阳。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600031867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","161027"],"gpt_icon":0},{"id":"2446837452","title":"百普赛斯(301080)6月24日主力资金净卖出322.41万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446837452","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446837452?lang=zh_cn&edition=full","pubTime":"2024-06-25 09:19","pubTimestamp":1719278396,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月24日收盘,百普赛斯报收于34.85元,下跌6.82%,换手率3.38%,成交量2.27万手,成交额8085.21万元。近5日资金流向一览见下表:百普赛斯融资融券信息显示,融资方面,当日融资买入630.93万元,融资偿还297.08万元,融资净买入333.85万元,连续3日净买入累计1417.24万元。融券方面,融券卖出7700.0股,融券偿还3300.0股,融券余量6.33万股,融券余额220.43万元。百普赛斯主营业务:提供重组蛋白等关键生物试剂产品及技术服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500010051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2445015674","title":"百普赛斯新提交6件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2445015674","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445015674?lang=zh_cn&edition=full","pubTime":"2024-06-24 11:46","pubTimestamp":1719200787,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日北京百普赛斯生物科技股份有限公司新提交6件商标注册申请。商标申请详情如下:今年以来北京百普赛斯生物科技股份有限公司新申请注册商标35件,截止目前公司共持有注册商标222件,另有65件商标尚在注册申请中。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400010136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","BK0216"],"gpt_icon":0},{"id":"2445093206","title":"百普赛斯(301080)6月21日主力资金净买入416.08万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445093206","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445093206?lang=zh_cn&edition=full","pubTime":"2024-06-24 09:15","pubTimestamp":1719191747,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月21日收盘,百普赛斯报收于37.4元,上涨2.02%,换手率2.34%,成交量1.57万手,成交额5807.4万元。近5日资金流向一览见下表:百普赛斯融资融券信息显示,融资方面,当日融资买入515.82万元,融资偿还321.17万元,融资净买入194.65万元。融券方面,融券卖出1800.0股,融券偿还6900.0股,融券余量5.89万股,融券余额220.1万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400001918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2442137897","title":"百普赛斯(301080)6月11日主力资金净卖出324.51万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442137897","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442137897?lang=zh_cn&edition=full","pubTime":"2024-06-12 09:17","pubTimestamp":1718155047,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月11日收盘,百普赛斯报收于37.87元,上涨3.39%,换手率2.8%,成交量1.87万手,成交额6955.83万元。6月11日的资金流向数据方面,主力资金净流出324.51万元,占总成交额4.67%,游资资金净流出306.93万元,占总成交额4.41%,散户资金净流入631.44万元,占总成交额9.08%。融券方面,融券卖出800.0股,融券偿还9800.0股,融券余量4.94万股,融券余额186.89万元。百普赛斯主营业务:提供重组蛋白等关键生物试剂产品及技术服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061200013997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2437080124","title":"百普赛斯:陈劲秋女士因个人原因申请辞去公司副总经理职务,她的离职不会影响公司相关工作的正常进行","url":"https://stock-news.laohu8.com/highlight/detail?id=2437080124","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437080124?lang=zh_cn&edition=full","pubTime":"2024-05-24 19:02","pubTimestamp":1716548525,"startTime":"0","endTime":"0","summary":"陈劲秋女士因个人原因申请辞去公司副总经理职务,她的离职不会影响公司相关工作的正常进行。公司正在苏州积极建设GMP级别的生产厂房,预计该生产基地2024年下半年投产,届时公司GMP级生物试剂的开发和生产能力将进一步提升,从而更有效地支持免疫细胞治疗药物的临床研究。公司持续保持对海外政策和市场动态的关注,及时有效采取措施应对风险,稳妥有效的实现公司全球化战略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052400039795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","BK1550","BK1571","BK1136","BK0216","BK1516","BK1127","06060"],"gpt_icon":0},{"id":"2435061827","title":"百普赛斯(301080)5月15日主力资金净卖出1370.52万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435061827","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435061827?lang=zh_cn&edition=full","pubTime":"2024-05-16 09:20","pubTimestamp":1715822441,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月15日收盘,百普赛斯报收于40.72元,下跌3.0%,换手率4.35%,成交量2.91万手,成交额1.19亿元。5月15日的资金流向数据方面,主力资金净流出1370.52万元,占总成交额11.53%,游资资金净流出392.6万元,占总成交额3.3%,散户资金净流入1763.12万元,占总成交额14.83%。融券方面,融券卖出4600.0股,融券偿还1900.0股,融券余量6.36万股,融券余额258.96万元。融资融券余额1.52亿元。百普赛斯主营业务:提供重组蛋白等关键生物试剂产品及技术服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051600010177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2435400321","title":"百普赛斯:公司将按照相关法律法规在定期报告中及时披露相应时点的股东持股情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2435400321","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435400321?lang=zh_cn&edition=full","pubTime":"2024-05-13 20:01","pubTimestamp":1715601661,"startTime":"0","endTime":"0","summary":"证券之星消息,百普赛斯05月13日在投资者关系平台上答复投资者关心的问题。目前,公司正搭建AI技术应用平台,将该技术应用于蛋白质的改造过程中。公司是一家专业提供重组蛋白、抗体等关键生物试剂及技术服务的高新技术企业,主要产品及服务应用于肿瘤、自身免疫疾病、心血管病、传染病等疾病的药物研发及生产环节。上市三年,三费不断激增,与公司营收增长完全不成比例。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051300023647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2433140347","title":"天风证券:给予百普赛斯买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2433140347","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433140347?lang=zh_cn&edition=full","pubTime":"2024-05-08 16:38","pubTimestamp":1715157492,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司近期对百普赛斯进行研究并发布了研究报告《常规业务增长趋势较好,研发储备充分》,本报告对百普赛斯给出买入评级,当前股价为47.43元。 百普赛斯 事件: 公司发布2023年年度报告,收入5.44亿元,同比增长14.59%,归母净利润1.54亿元,同比减少24.61%,扣非净利润1.40亿元,同比减少23.42%。最新盈利预测明细如下:该股最近90天内共有13家机构给出评级,买入评级12家,增持评级1家;过去90天内机构目标均价为52.76。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800028502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","601162"],"gpt_icon":0},{"id":"2433711156","title":"5月8日百普赛斯涨6.75%,圆信永丰兴源灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433711156","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433711156?lang=zh_cn&edition=full","pubTime":"2024-05-08 16:23","pubTimestamp":1715156622,"startTime":"0","endTime":"0","summary":"证券之星消息,5月8日百普赛斯涨6.75%,收盘报47.43元,换手率15.61%,成交量10.47万手,成交额4.88亿元。根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为圆信永丰兴源灵活配置混合A。圆信永丰兴源灵活配置混合A目前规模为7.1亿元,最新净值1.6842,较上一交易日上涨0.44%,近一年下跌13.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800027496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","BK0216"],"gpt_icon":0},{"id":"2433476361","title":"百普赛斯(301080)5月7日主力资金净买入3028.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433476361","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433476361?lang=zh_cn&edition=full","pubTime":"2024-05-08 09:15","pubTimestamp":1715130929,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月7日收盘,百普赛斯报收于44.43元,上涨3.93%,换手率11.42%,成交量7.65万手,成交额3.35亿元。5月7日的资金流向数据方面,主力资金净流入3028.59万元,占总成交额9.04%,游资资金净流入1482.16万元,占总成交额4.43%,散户资金净流出4510.75万元,占总成交额13.47%。融券方面,融券卖出1.12万股,融券偿还1.58万股,融券余量7.02万股,融券余额311.99万元。百普赛斯主营业务:提供重组蛋白等关键生物试剂产品及技术服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800013919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","BK0216"],"gpt_icon":0},{"id":"2433453324","title":"百普赛斯涨10.67%,开源证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2433453324","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433453324?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:40","pubTimestamp":1714984830,"startTime":"0","endTime":"0","summary":"今日百普赛斯涨10.67%,收盘报42.75元。2024年4月26日,开源证券研究员余汝意,汪晋发布了对百普赛斯的研报《公司信息更新报告:常规业务持续高增长,高费用影响短期利润》,该研报对百普赛斯给出“买入”评级。此外,东吴证券研究员朱国广,张坤,首创证券研究员王斌,陈智博近期也对该股发布了研报,同样给出“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为西南证券的杜向阳。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600015398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","161027"],"gpt_icon":0},{"id":"2430720693","title":"开源证券:给予百普赛斯买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2430720693","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430720693?lang=zh_cn&edition=full","pubTime":"2024-04-26 22:40","pubTimestamp":1714142443,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,汪晋近期对百普赛斯进行研究并发布了研究报告《公司信息更新报告:常规业务持续高增长,高费用影响短期利润》,本报告对百普赛斯给出买入评级,当前股价为37.54元。公司2023年收入端增长稳健,2024年Q1受下游需求放缓影响,业绩增速有所放缓,及费用端增长较快影响利润端阶段性承压。最新盈利预测明细如下:该股最近90天内共有7家机构给出评级,买入评级6家,增持评级1家;过去90天内机构目标均价为48.87。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600057927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","301080"],"gpt_icon":0},{"id":"2430309418","title":"东吴证券:给予百普赛斯买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2430309418","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430309418?lang=zh_cn&edition=full","pubTime":"2024-04-25 07:25","pubTimestamp":1714001118,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广,张坤近期对百普赛斯进行研究并发布了研究报告《2023年报&2024一季报点评:利润短期承压,产品研发与海外市场逐步进入收获期》,本报告对百普赛斯给出买入评级,当前股价为35.77元。当前股价对应2024-2026年PE分别为27/21/17×,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有3家机构给出评级,买入评级2家,增持评级1家;过去90天内机构目标均价为54.68。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500012715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","301080"],"gpt_icon":0},{"id":"2430921964","title":"百普赛斯(301080)2024年一季报简析:增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2430921964","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430921964?lang=zh_cn&edition=full","pubTime":"2024-04-25 06:18","pubTimestamp":1713997103,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期百普赛斯发布2024年一季报。根据财报显示,本报告期中百普赛斯增收不增利。截至本报告期末,公司营业总收入1.46亿元,同比上升6.67%,归母净利润3067.21万元,同比下降31.91%。从公司近一年的财务报表来看,最新年度财报中利润同比下降32%。报告期内公司持续深入拓展细胞治疗相关的产品和技术服务,开发出一系列可支持细胞疗法开发的产品和技术平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500012157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","BK0216"],"gpt_icon":0},{"id":"2429824984","title":"百普赛斯(301080)3月31日股东户数1.43万户,较上期增加9.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429824984","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429824984?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:10","pubTimestamp":1713949849,"startTime":"0","endTime":"0","summary":"证券之星消息,近日百普赛斯披露,截至2024年3月31日公司股东户数为1.43万户,较12月31日增加1201.0户,增幅为9.16%。户均持股数量由上期的9157.0股减少至8388.0股,户均持股市值为34.23万元。在生物制品行业个股中,百普赛斯股东户数低于行业平均水平,截至3月31日,生物制品行业平均股东户数为3.35万户。从股价来看,2023年12月31日至2024年3月31日,百普赛斯区间跌幅为30.76%,在此期间股东户数增加1201.0户,增幅为9.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400035895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-10-18","address":"北京市大兴区北京经济技术开发区宏达北路8号4幢4层","stockEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.012},{"period":"3month","weight":0.0154},{"period":"6month","weight":-0.2569},{"period":"1year","weight":-0.3607},{"period":"ytd","weight":-0.38}],"companyName":"北京百普赛斯生物科技股份有限公司","boardCode":"AI0073","perCapita":"4685股","boardName":"研究和试验发展","registeredCapital":"12000万元","compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0118},{"period":"3month","weight":-0.0271},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":0.0025}],"survey":" 北京百普赛斯生物科技股份有限公司是一家专业提供重组蛋白等关键生物试剂产品及技术服务的高新技术企业。公司主要产品为重组蛋白、试剂盒、抗体、生物分析检测服务。2019年5月获得“中国外贸出口先导指数样本企业”荣誉称号、2020年3月入围科技部疫情防控先进技术成果和创新产品。公司于2020年10月获得亦庄高科技高成长20强;于2020年7月获得2020年北京市“专精特新”中小企业的荣誉称号。","serverTime":1721449129174,"listedPrice":112.5,"stockholders":"14306人(较上一季度增加9.16%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百普赛斯(301080)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百普赛斯(301080)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百普赛斯,301080,百普赛斯股票,百普赛斯股票老虎,百普赛斯股票老虎国际,百普赛斯行情,百普赛斯股票行情,百普赛斯股价,百普赛斯股市,百普赛斯股票价格,百普赛斯股票交易,百普赛斯股票购买,百普赛斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百普赛斯(301080)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百普赛斯(301080)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}